Report Summary
Eternity Insights can provide a deep dive research report highlighting the market and competitive in-telligence across the key segments of the market. The report also considers the impact of COVID-19 on the global Asthma and COPD Drugs market. The report considers 2018-2020 historic period, 2021 as base year, and 2022-2028 as forecast period. The report includes quantitative analysis of the market supported by the mar-ket drivers, challenges, and trends to accurately map the market scenario and competition.
Asthma and COPD Drugs market report is based on robust research methodology designed using blend of research ap-proaches developed using secondary/desk research and validated through the primary research and expert insights. Eternity Insights also uses paid data bases such as FACIVA, Hoovers, and other bench-marking and forecasting tools to provide accurate statistical analysis of supply and demand trends.
To learn more about this report
Key Research Highlights: Market Drivers
The Asthma and COPD Drugs market is estimated to expand at a considerable growth rate during the forecast period ow-ing to increasing prevalence of venous diseases and increasing new product approvals to cater this demand. Rise in the awareness about the diseases, increasing importance of early diagnosis, and growing spending on chronic diseases are poised to boost the market growth. Moreover, the key players in the market are investing in research and development of technologically advanced products leading to increased utilization of the Asthma and COPD Drugs products across developed and developing countries of the world.
Key Research Highlights: Market Restrains
Limited awareness about the diseases, high cost of products, low economical condition, and lack of favorable insurance systems restricts the adoption of Asthma and COPD Drugs products across developing regions of the globe. However, launch of new products with low cost and increasing efforts for market penetration in these regions can offer lucrative growth opportunities for the players in the Asthma and COPD Drugs market.
To learn more about this report
Key Research Highlights: Trends
Increasing research and development spending on Asthma and COPD Drugs development has been the leading industry trend of Asthma and COPD Drugs market
The leading players in the market are focused on developing products which are cost effective and high quality to tap the huge unaddressed opportunities in the developing regions. This can be wit-nessed from the increasing spending on research and development and growing number of new product approvals.
Global Asthma and COPD Drugs Market Size, 2018-2028 (USD MILLION)
To learn more about this report
Market Segmentation
Report Attributes |
Details |
The market size value in 2021 |
USD XX.XX Million |
CAGR (2021 - 2028) |
XX.XX % |
The Revenue forecast in 2028 |
USD XX.XX Million |
Base year for estimation |
2021 |
Historical data |
2018-2019 |
Forecast period |
2022-2028 |
Quantitative units |
- Revenue in USD Million
- CAGR from 2021 to 2028
|
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
By Type Outlook, Application Outlook, Regional Outlook |
By Type Outlook |
COPD, Asthma, Other |
By Application Outlook |
Combination Products, Leukotriene Antagonists (LTA), Inhaled Corticosteroids (ICS), Anticholinergics, Short Acting Beta Agonists(SABA), Long Acting Beta Agonists (LABA), Others |
Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Country scope |
U.S., Canada, U.K., Germany, France, BENELUX, China, India, Japan, South Korea, Brazil, Saudi Arabia, UAE, Turkey |
Key companies profiled |
GlaxoSmithKline, Novartis, Merck, Abbott Laboratories, Boehringer Ingelheim, AstraZeneca, Roche Holding AG, Teva Pharmaceutical Industries, Vectura Group, Pfizer |
Customization Available |
Yes, the report can be tailored to meet your specific requirements. |
Key Market Players
- GlaxoSmithKline
- Novartis
- Merck
- Abbott Laboratories
- Boehringer Ingelheim
- AstraZeneca
- Roche Holding AG
- Teva Pharmaceutical Industries
- Vectura Group
- Pfizer
ASTHMA AND COPD DRUGS Market, By Type
ASTHMA AND COPD DRUGSMarket, By Application
- Combination Products
- Leukotriene Antagonists (LTA)
- Inhaled Corticosteroids (ICS)
- Anticholinergics
- Short Acting Beta Agonists(SABA)
- Long Acting Beta Agonists (LABA)
- Others
Key Benefits To The Stake Holders
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) and volume (Tons) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Table Of Contents
Table of Contents
1 Asthma and COPD Drugs Market Overview
1.1 Asthma and COPD Drugs Product Overview
1.2 Asthma and COPD Drugs Market Segment by Type
1.2.1 COPD
1.2.2 Asthma
1.3 Global Asthma and COPD Drugs Market Size by Type
1.3.1 Global Asthma and COPD Drugs Sales and Growth by Type
1.3.2 Global Asthma and COPD Drugs Sales and Market Share by Type (2013-2018)
1.3.3 Global Asthma and COPD Drugs Revenue and Market Share by Type (2013-2018)
1.3.4 Global Asthma and COPD Drugs Price by Type (2013-2018)
2 Global Asthma and COPD Drugs Market Competition by Company
2.1 Global Asthma and COPD Drugs Sales and Market Share by Company (2013-2018)
2.2 Global Asthma and COPD Drugs Revenue and Share by Company (2013-2018)
2.3 Global Asthma and COPD Drugs Price by Company (2013-2018)
2.4 Global Top Players Asthma and COPD Drugs Manufacturing Base Distribution, Sales Area, Product Types
2.5 Asthma and COPD Drugs Market Competitive Situation and Trends
2.5.1 Asthma and COPD Drugs Market Concentration Rate
2.5.2 Global Asthma and COPD Drugs Market Share of Top 5 and Top 10 Players
2.5.3 Mergers & Acquisitions, Expansion
3 Asthma and COPD Drugs Company Profiles and Sales Data
3.1 GlaxoSmithKline
3.1.1 Company Basic Information, Manufacturing Base and Competitors
3.1.2 Asthma and COPD Drugs Product Category, Application and Specification
3.1.3 GlaxoSmithKline Asthma and COPD Drugs Sales, Revenue, Price and Gross Margin(2013-2018)
3.1.4 Main Business Overview
3.2 Novartis
3.2.1 Company Basic Information, Manufacturing Base and Competitors
3.2.2 Asthma and COPD Drugs Product Category, Application and Specification
3.2.3 Novartis Asthma and COPD Drugs Sales, Revenue, Price and Gross Margin(2013-2018)
3.2.4 Main Business Overview
3.3 Merck
3.3.1 Company Basic Information, Manufacturing Base and Competitors
3.3.2 Asthma and COPD Drugs Product Category, Application and Specification
3.3.3 Merck Asthma and COPD Drugs Sales, Revenue, Price and Gross Margin(2013-2018)
3.3.4 Main Business Overview
3.4 Abbott Laboratories
3.4.1 Company Basic Information, Manufacturing Base and Competitors
3.4.2 Asthma and COPD Drugs Product Category, Application and Specification
3.4.3 Abbott Laboratories Asthma and COPD Drugs Sales, Revenue, Price and Gross Margin(2013-2018)
3.4.4 Main Business Overview
3.5 Boehringer Ingelheim
3.5.1 Company Basic Information, Manufacturing Base and Competitors
3.5.2 Asthma and COPD Drugs Product Category, Application and Specification
3.5.3 Boehringer Ingelheim Asthma and COPD Drugs Sales, Revenue, Price and Gross Margin(2013-2018)
3.5.4 Main Business Overview
3.6 AstraZeneca
3.6.1 Company Basic Information, Manufacturing Base and Competitors
3.6.2 Asthma and COPD Drugs Product Category, Application and Specification
3.6.3 AstraZeneca Asthma and COPD Drugs Sales, Revenue, Price and Gross Margin(2013-2018)
3.6.4 Main Business Overview
3.7 Roche Holding AG
3.7.1 Company Basic Information, Manufacturing Base and Competitors
3.7.2 Asthma and COPD Drugs Product Category, Application and Specification
3.7.3 Roche Holding AG Asthma and COPD Drugs Sales, Revenue, Price and Gross Margin(2013-2018)
3.7.4 Main Business Overview
3.8 Teva Pharmaceutical Industries
3.8.1 Company Basic Information, Manufacturing Base and Competitors
3.8.2 Asthma and COPD Drugs Product Category, Application and Specification
3.8.3 Teva Pharmaceutical Industries Asthma and COPD Drugs Sales, Revenue, Price and Gross Margin(2013-2018)
3.8.4 Main Business Overview
3.9 Vectura Group
3.9.1 Company Basic Information, Manufacturing Base and Competitors
3.9.2 Asthma and COPD Drugs Product Category, Application and Specification
3.9.3 Vectura Group Asthma and COPD Drugs Sales, Revenue, Price and Gross Margin(2013-2018)
3.9.4 Main Business Overview
3.10 Pfizer
3.10.1 Company Basic Information, Manufacturing Base and Competitors
3.10.2 Asthma and COPD Drugs Product Category, Application and Specification
3.10.3 Pfizer Asthma and COPD Drugs Sales, Revenue, Price and Gross Margin(2013-2018)
3.10.4 Main Business Overview
4 Asthma and COPD Drugs Market Status and Outlook by Regions
4.1 Global Market Status and Outlook by Regions
4.1.1 Global Asthma and COPD Drugs Market Size and CAGR by Regions
4.1.2 North America
4.1.3 Asia-Pacific
4.1.4 Europe
4.1.5 South America
4.1.6 Middle East and Africa
4.2 Global Asthma and COPD Drugs Sales and Revenue by Regions
4.2.1 Global Asthma and COPD Drugs Sales and Market Share by Regions (2013-2018)
4.2.2 Global Asthma and COPD Drugs Revenue and Market Share by Regions (2013-2018)
4.2.3 Global Asthma and COPD Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
4.3 North America Asthma and COPD Drugs Sales, Revenue, Price and Gross Margin
4.3.1 United States
4.3.2 Canada
4.3.3 Mexico
4.4 Europe Asthma and COPD Drugs Sales, Revenue, Price and Gross Margin
4.4.1 Germany
4.4.2 UK
4.4.3 France
4.4.4 Italy
4.4.5 Russia
4.4.6 Turkey
4.5 Asia-Pacific Asthma and COPD Drugs Sales, Revenue, Price and Gross Margin
4.5.1 China
4.5.2 Japan
4.5.3 Korea
4.5.4 Southeast Asia
4.5.4.1 Indonesia
4.5.4.2 Thailand
4.5.4.3 Malaysia
4.5.4.4 Philippines
4.5.4.5 Vietnam
4.5.5 India
4.5.6 Australia
4.6 South America Asthma and COPD Drugs Sales, Revenue, Price and Gross Margin
4.6.1 Brazil
4.7 Middle East and Africa Asthma and COPD Drugs Sales, Revenue, Price and Gross Margin
4.7.1 Egypt
4.7.2 GCC Countries
5 Asthma and COPD Drugs Application/End Users
5.1 Asthma and COPD Drugs Segment by Application
5.1.1 Combination Products
5.1.2 Leukotriene Antagonists (LTA)
5.1.3 Inhaled Corticosteroids (ICS)
5.1.4 Anticholinergics
5.1.5 Short Acting Beta Agonists(SABA)
5.1.6 Long Acting Beta Agonists (LABA)
5.1.7 Others
5.2 Global Asthma and COPD Drugs Product Segment by Application
5.2.1 Global Asthma and COPD Drugs Sales by Application
5.2.2 Global Asthma and COPD Drugs Sales and Market Share by Application (2013-2018)
6 Global Asthma and COPD Drugs Market Forecast
6.1 Global Asthma and COPD Drugs Sales, Revenue Forecast (2018-2025)
6.1.1 Global Asthma and COPD Drugs Sales and Growth Rate Forecast (2018-2025)
6.1.1 Global Asthma and COPD Drugs Revenue and Growth Rate Forecast (2018-2025)
6.2 Global Asthma and COPD Drugs Forecast by Regions
6.2.1 North America Asthma and COPD Drugs Sales and Revenue Forecast (2018-2025)
6.2.2 Europe Asthma and COPD Drugs Sales and Revenue Forecast (2018-2025)
6.2.3 Asia-Pacific Asthma and COPD Drugs Sales and Revenue Forecast (2018-2025)
6.2.3.1 China
6.2.3.2 Japan
6.2.3.3 Korea
6.2.3.4 Southeast Asia
6.2.3.5 India
6.2.3.6 Australia
6.2.4 South America Asthma and COPD Drugs Sales and Revenue Forecast (2018-2025)
6.2.5 Middle East and Africa Asthma and COPD Drugs Sales and Revenue Forecast (2018-2025)
6.2.5.1 Egypt
6.2.5.2 GCC Countries
6.3 Asthma and COPD Drugs Forecast by Type
6.3.1 Global Asthma and COPD Drugs Sales and Revenue Forecast by Type (2018-2025)
6.3.2 COPD Gowth Forecast
6.3.3 Asthma Gowth Forecast
6.4 Asthma and COPD Drugs Forecast by Application
6.4.1 Global Asthma and COPD Drugs Sales Forecast by Application (2018-2025)
6.4.2 Global Asthma and COPD Drugs Forecast in Combination Products
6.4.3 Global Asthma and COPD Drugs Forecast in Leukotriene Antagonists (LTA)
7 Asthma and COPD Drugs Upstream Raw Materials
7.1 Asthma and COPD Drugs Key Raw Materials
7.1.1 Key Raw Materials
7.1.2 Key Raw Materials Price
7.1.3 Raw Materials Key Suppliers
7.2 Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Asthma and COPD Drugs Industrial Chain Analysis
8 Marketing Strategy Analysis, Distributors
8.1 Marketing Channel
8.1.1 Direct Marketing
8.1.2 Indirect Marketing
8.1.3 Marketing Channel Development Trend
8.2 Distributors
8.3 Downstream Customers
9 Research Findings and Conclusion
Appendix
Methodology/Research Approach
Research Programs/Design
Market Size Estimation
Market Breakdown and Data Triangulation
Data Source
Secondary Sources
Primary Sources
Disclaimer